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Validation of repeated endothelial 
Function Measurements Using 
endoPaT in stroke
Aina S. Hansen, Jawad H. Butt, Sonja Holm-Yildiz, William Karlsson and Christina Kruuse*
Department of Neurology, Stroke Unit, Neurovascular Research Unit, Herlev-Gentofte University Hospital, Herlev, Denmark
Background: Decreased endothelial function (EF) may be a prognostic marker for 
stroke. Measuring pharmacological effects on EF may be of interest in the development 
of personalized medicine for stroke prevention. In this study, we assessed the reliability 
of repeated EF measurements using a pulse amplitude tonometry technology in acute 
stroke patients. Similarly, reliability was tested in healthy subjects devoid of vascular 
disease to estimate reactivity and reliability in a younger non-stroke population.
Materials and methods: EF was assessed using the EndoPAT2000 in 20 healthy 
volunteers (men 50%, mean age 35.85 ± 3.47 years) and 21 stroke patients (men 52%, 
mean age 66.38 ± 2.85 years, and mean NIHSS 4.09 ± 0.53) under standardized con-
ditions. EF was measured as the reactive hyperemia index (RHI), logarithm of RHI (lnRHI), 
and Framingham RHI (fRHI). Measurements were separated by 1.5 and 24 h to assess 
same-day and day-to-day reliability, respectively.
results: Fair to moderate correlations of measurements [intraclass correlation coeffi-
cient (ICC)same-day 0.29 and ICCday-to-day 0.52] were detected in healthy subjects. In stroke 
patients, we found moderate to substantial correlation of both same-day and day-to-day 
repeated measurements (ICCsame-day 0.40 and ICCday-to-day 0.62). fRHI compared with RHI 
and lnRHI showed best reliability.
conclusion: Repeated measurements of fRHI in stroke patients show moderate reliabil-
ity on same-day and substantial on day-to-day measurements. Likewise, in healthy sub-
jects there was substantial reliability on day-to-day measurement, but only moderate on 
same-day measurements. In general, day-to-day correlation of repeated EF measurements 
was far better than that of same-day measurements, which ranged from poor to moder-
ate depending on the specific outcome measure of EF. A possible carryover effect should 
be considered if same-day repeated testing of drug effects is applied in future studies.
Keywords: endothelial function, stroke, validation, endoPaT, vasomotor reactivity
BacKgrOUnD
Studying drug effects on endothelial function (EF) in stroke patients could add to the understanding 
of stroke pathophysiology, effects of new treatment, and identify patients at increased risk of stroke.
Reduced EF is associated with an increased risk of stroke (1–3), cardiovascular diseases (4), 
hypertension (5), hypercholesterolemia (5), type II diabetes (6, 7), and obesity (8). However, meth-
ods for evaluating EF are not yet agreed upon (9–12).
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Endothelial function determination in large-scale risk stratifi-
cation of stroke patients must be reliable, non-invasive, and widely 
applicable, as well as a good predictor for the risk of future vascular 
events. In addition, improvement in test results must be related 
to a subsequent reduction in risk of stroke. If fulfilling these 
requirements, measurement of EF could be a new tool for further 
evaluating and advising stroke patients.
Non-invasive measurements of EF have been used extensively 
in vascular research (9). The most frequently applied method is 
flow-mediated dilation (FMD) assessed by brachial artery ultra-
sound (13). This method is reliable on repeated measurements 
(14) and associated with cardiovascular risk factors (5, 15, 16), but 
show high dependency on operator experience level with special 
training required (12). Computerized analysis of pulse amplitude 
tonometry (PAT) in the index finger after reactive hyperemia 
has gained increasing interest as an easy accessible non-invasive 
method for assessment of EF (17, 18). Such automatized method 
for measuring EF requires little training of the operator and is thus 
easy to apply in studies without extensive training of personal.
Digital vascular response to reactive hyperemia is found to be 
predominantly dependent on nitric oxide-mediated vasodilation 
in healthy subjects (19) and has been shown to be attenuated in 
patients with coronary microvascular endothelial dysfunction 
(20). Large community-based cohort studies reported an associa-
tion between EF and cardiovascular risk factors (5, 21). However, 
the risk factor profile for FMD and digital vascular response dif-
fered, with the latter more associated with metabolic dysfunction. 
Hence, FMD and EndoPAT probably reflect different aspects of 
vascular function in selected vascular beds and vessel size (5, 21). 
A study investigating the relationship of digital EF and stroke 
subtypes according to the TOAST classification (22) found varia-
tions in EF according to stroke subtypes with best EF in patients 
with cardioembolic stroke and worst in lacunar and large artery 
stroke (23).
Previous studies found good correlation of repeated digital 
EF measurements using PAT technology performed on different 
days in healthy volunteers (24–28) and in patients with coronary 
artery disease (CAD) (14). However, the technique has not yet 
been validated in stroke patients. Validation in stroke patients is 
important due to vascular instability in the acute phase poststroke 
that may affect the reliability of measurements (29, 30).
The primary outcome of this study was to determine the 
reliability of repeated digital EF measurements in patients with 
acute stroke on same-day and day-to-day measurements. In 
addition, we wish to assess repeated digital EF measurements in 
healthy volunteers to correlate our results with those previously 
published.
The results from this study are important for calculating 
sufficient sample sizes for future studies using this technique in 
stroke patients and to assess if repeated PAT measurements are 
valid in acute stroke.
MaTerials anD MeThODs
subjects
Only subjects above 18 years of age were included after sign-
ing informed consent. Twenty healthy subjects were recruited 
from the hospital staff and the local community. They did not 
take medications and had no prior history of cardiovascular 
disease, arrhythmias, diabetes, hypercholesterolemia, or 
hypertension. Twenty-two patients with non-cardioembolic 
acute stroke were recruited from patients admitted to the 
Stroke Unit, Department of Neurology, Herlev-Gentofte 
University Hospital. Stroke was defined as acute neurological 
deficits lasting for more than 24 h with radiological evidence 
of a corresponding acute ischemic brain lesion (CT or MRI), 
and stroke severity was assessed by NIHSS. Measurements 
were concluded within 5 days of stroke onset. Five of 22 stroke 
patients used one or more vasoactive medication (calcium 
antagonists: 3; angiotensin-receptor blockers: 3). On the days 
of examination, administration of medication was postponed 
until measurements were concluded.
Procedure
Subjects were instructed to fast for 8 h, and further to refrain from 
smoking, alcohol- and xanthine-containing food, and beverages 
for 12 h prior to EF testing. Measurement of EF was performed 
two times on one day, separated by 1.5 h, and on the following 
day, separated by exactly 24 h.
Endothelial function and arterial stiffness were assessed by 
digital plethysmography using the EndoPAT2000-device (Itamar 
Medical Ltd., Caesarea, Israel). Measurements were conducted 
in accordance with conditions specified by the manufacturer. All 
tests were performed in the supine position in quiet surround-
ings, on a comfortable bed in a dimly lit room, with a temperature 
of 21–24°C. Pneumatic probes were placed on each index finger 
and a blood pressure cuff on one arm. With the arms at rest on 
comfortable arm supports, probes were inflated to a subdiastolic 
pressure to avoid distal venous pooling, thereby inhibiting the 
veno-arteriolar vasoconstriction reflex (31). The recording was 
initiated after 25 min of rest. After 5 min baseline recording, the 
blood pressure cuff was inflated to 60 mmHg above systolic blood 
pressure and no less than 200 mmHg. Occlusion was confirmed 
by visual confirmation of complete attenuation of the PAT signal 
from the test arm. After 5 min occlusion, the cuff was deflated and 
the recording continued for 5 min during the reactive hyperemia 
phase. Recordings from the non-occluded arm served as an 
internal control correcting for systemic changes in vascular tone.
calculation of eF
Endothelial function and arterial stiffness were calculated using 
the EndoPAT software package version 3.4.4. EF was given as 
the reactive hyperemia index (RHI), the natural logarithm of 
RHI (lnRHI), and Framingham RHI (fRHI). Arterial stiffness as 
the augmentation index (AI) and AI standardized to a pulse of 
75/min (AI@75).
Reactive hyperemia index was calculated as the index of signal 
amplitude pre-to-post occlusion in the occluded arm, divided by 
the same ratio in the control arm. Calculation of fRHI was done 
according to Hamburg et al (32). Determination of AI is based on 
computerized averaging and analysis of multiple pulse waveforms 
obtained during the baseline measurement on the occluded arm. 
AI@75 is corrected for differences in pulse by normalization to a 
heart rate of 75 beats/min.
TaBle 1 | Demographic data.
stroke healthy
Age (years) 67.27 ± 1.63 35.9 ± 3.47
Sex (male) 0.55 0.50
BMI 25.25 ± 0.49 22.73 ± 0.41
DBP 82.23 ± 1.49 70.82 ± 1.07
SBP 142.72 ± 2.61 118.78 ± 2.02
NIHSS 4.09 ± 0.53 0.00 ± 0.00
Reactive hyperemia index 2.24 ± 0.09 1.93 ± 0.06
Logarithm of RHI 0.76 ± 0.04 0.63 ± 0.03
Framingham RHI 0.57 ± 0.05 0.41 ± 0.05
Augmentation index 27.91 ± 2.75 −3.37 ± 1.76
AI standardized to a pulse of 75/min 21.86 ± 2.34 −12.69 ± 1.74
All results are given as mean ± SEM.
TaBle 2 | reliability of repeated testing in stroke patients.
Mean 
difference ± sD
p-Value Pearson’s r intraclass 
correlation 
coefficient  
(95% ci)
same-day
Reactive 
hyperemia  
index (RHI)
0.54 ± 0.14 0.68 0.27 0.25 (−0.18; 0.60)
Logarithm of  
RHI (lnRHI)
0.22 ± 0.05 0.89 0.41 0.40 (0.00; 0.69)
Framingham  
RHI (fRHI)
0.27 ± 0.06 0.97 0.64 0.64 (0.32; 0.83)
Augmentation 
index (AI)
4.83 ± 0.92 0.65 0.96 0.96 (0.91; 0.98)
AI standardized 
to a pulse of  
75/min (AI@75)
5.16 ± 0.88 0.93 0.94 0.94 (0.87; 0.98)
Day-to-day
RHI 0.47 ± 0.58 0.74 0.55 0.56 (0.20; 0.79)
lnRHI 0.19 ± 0.18 0.94 0.60 0.62 (0.29; 0.82)
fRHI 0.26 ± 0.23 0.64 0.72 0.72 (0.44; 0.87)
AI 5.51 ± 4.09 0.51 0.95 0.95 (0.89; 0.98)
AI@75 6.70 ± 3.87 0.15 0.92 0.92 (0.82; 0.97)
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Reactive hyperemia index, lnRHI, fRHI, AI, and AI@75 
data were tested for normality by Shapiro–Wilks test and visual 
inspection of histograms and Q–Q plots. Differences between 
mean values were assessed by paired t-test. Correlation of same-
day and day-to-day measurements was calculated as the Pearson’s 
product-moment correlation coefficient (Pearson’s r) and intra-
class correlation coefficients (ICCs). In accordance with Landis 
and Koch, we interpreted ICC values as follows: >0.80 was almost 
perfect, 0.61–0.80 was substantial, 0.41–0.60 was moderate, 
0.21–0.40 was fair, 0.20–0.00 was slight, and <0.00 was poor (33). 
The correlation of measurements is presented as Bland–Altman 
plots. All statistical calculations were performed using Rstudio 
(Rstudio, Boston, MA, USA) applying standard packages and 
packages “dplyr,” “BlandAltmanLeh,” “Stats,” and “ICC.”
resUlTs
We included two different populations that were analyzed 
separately: (1) healthy individuals (n = 20, men 50%, mean age 
35.85 ±  3.47 years) and (2) stroke patients (n =  22, men 52%, 
mean age 66.38  ±  2.85  years). Population characteristics are 
shown in Table 1. Only intraindividual assessment within each 
group was performed, as difference in response between healthy 
subjects and stroke patients is already known to exist and not the 
scope of this paper.
All data sets were accepted as suitable for parametric test-
ing. However, it should be noted that according to the manu -
fac turer of the EndoPAT device, RHI data represent a skewed 
distribution.
stroke Patients
We found no significant difference between same-day or day- 
to-day measurements (p = 0.96 and 0.76, respectively). Correlation 
coefficients showed moderate to substantial reliability of day- 
to-day measurements with ICC values ranging from 0.56 to 0.72 
for EF measurements. Data for same-day measurements showed 
more varied results with ICC values from 0.25 to 0.64. Repeated 
measurements of fRHI and lnRHI were more reliable than RHI 
both on same-day and day-to-day measurements (Table  2). 
Measurements of arterial stiffness (AI@75) showed almost perfect 
agreement on same-day (ICC = 0.94) and day-to-day (ICC = 0.91) 
measurements.
We found no evidence of systematic errors in Bland–Altman 
plots (Figure 1). However, the plots show one distinct outlier. We 
analyzed the data for this specific patient and found no errors 
leading to exclusion of the patient’s data.
healthy subjects
For day-to-day measurements, there was no significant difference 
between mean values (p =  0.82). For same-day measurements, 
the difference in mean values was close to significant (p = 0.05). 
Correlation coefficients showed moderate to substantial reliability 
of day-to-day measurements with ICC values ranging from 0.51 
to 0.67. Same-day measurements showed fair to moderate reliabil-
ity with ICC values ranging from 0.28 to 0.51 (Table 3). Reliability 
of arterial stiffness measurements (AI@75) showed substantial 
agreement on same-day (ICC  =  0.76) and an almost perfect 
agreement on day-to-day measurement (ICC = 0.82). The Bland– 
Altman plots (Figure 1) show no evidence of systematic error.
DiscUssiOn
This study provides interesting data on the reliability of EF testing 
in patients with acute stroke by measuring the digital vascular 
response to reactive hyperemia. We found moderate to substan-
tial correlation on day-to-day EF measurements in both healthy 
subjects and stroke patients.
We found worse correlations of same-day repeated measure-
ments in both groups. Same-day measurements in healthy sub-
jects also showed trends toward a difference in EF.
The digital vascular response is calculated from the change in 
pulse wave amplitude caused by vasodilation in response to reac-
tive hyperemia. If an ample amount of time between measure-
ments is not applied for the vessels to regain vascular steady state, 
a carryover effect may influence the subsequent measurement. 
FigUre 1 | Bland–altman plot for Framingham reactive hyperemia index data.  Δ Stroke patients, ○ healthy subjects.
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This could explain the poor correlation of same-day measure-
ments in both groups.
We found that in healthy subjects EF measurements showed a 
worse correlation between test and retest compared with the stroke 
patients. Such correlation could reflect a larger heterogeneity of 
the healthy subjects than of the stroke patients; the mean age was 
significantly lower in healthy subjects, with more widespread 
age distribution within the group compared with the stroke 
patients. However, due to the modest sample size of this study 
we cannot discard that the difference may be caused by random 
variation.
Previous studies have assessed reliability of EF measurements 
using EndoPAT, in healthy individuals and patients with CAD 
(Table 4). Similar to our findings, these studies found substantial 
reliability of EF measurements performed on two separate days 
reporting ICC values between 0.56 and 0.83 (14, 24–27). Only 
two studies investigated the reliability of same-day measurements 
although with diverging results. One reported good correlation 
of repeated measurements after 30  min (ICC 0.68) (14), while 
the other study indicated a possible carryover effect of repeated 
measurements after 30 min (28).
The study in CAD patients (14) is of particular interest in rela-
tion to our study, as these patients have known vascular disease 
but show good correlation of both day-to-day and same-day 
measurements. However, the group of patients in this study would 
be assumed to have a steady vascular function because they had 
no cardiovascular incident 9 months prior to testing. No other 
studies seem to have investigated reliability of measurements in 
patients with acute vascular disease.
Endothelial cell activation and vascular variability have gained 
increasing interest in stroke research (29, 30). Thus, investigat-
ing the reliability of EF testing in the acute phase poststroke is 
important for future studies in this area. Compared with other 
methods used for assessing EF, the use of the digital PAT has the 
advantage of being almost operator independent, with standardized 
measurements and calculations. In addition, the technique is 
TaBle 4 | comparison with studies reporting test–retest reliability.
reference number of patients 
(M/F)
Patients Mean age interval between 
measurements
Measured value Pearson’s r icc
Hansen et al. (current study) 20 (10/10) Healthy 35.9 ± 3.47a 1.5 h fRHI 0.51 0.42
AI@75 0.78 0.76
24 h fRHI 0.66 0.67
AI@75 0.84 0.82
Hansen et al. (current study) 22 (12/10) Acute stroke 
patients
67.27 ± 1.63a 1.5 h fRHI 0.64 0.64
AI@75 0.94 0.94
24 h fRHI 0.72 0.72
AI@75 0.92 0.92
Tomfohr et al. (24) 12 (11/1) Healthy 26.8 1–7 days – 0.76 0.73
Reisner et al. (25) 113 (73/40) Healthy 40 ± 12.6b 1 day fRHI 0.56 0.56
AI 0.84 0.84
McCrea et al. (26) 20 (14/6) Disease free 
overweight
41.2 ± 2.4a Mean 19.5 ± 6.2a days RHI 0.68 0.74
fRHI 0.77 0.77
AI 0.89 0.83
AI@75 0.88 0.81
Selamet Tierney et al. (27) 30 (17/13) Healthy 17.3 (13.3–19.7)c >7 days RHI – 0.78
fRHI – 0.83
Onkelinx et al. (14) 18 (18/0) CAD 68.3 ± 7.8b 30 min RHI – 0.68
2 days RHI – 0.73
M, male; F, female; ICC, intraclass correlation coefficient; fRHI, Framingham reactive hyperemia index; AI@75, AI normalized to pulse 75/min; AI, augmentation index; RHI, reactive 
hyperemia index; CAD, coronary artery disease.
aMean ± SEM.
bMean ± SD.
cMean (range).
TaBle 3 | reliability of repeated testing in healthy subjects.
Mean 
difference ± sD
p-Value Pearson’s r intraclass 
correlation 
coefficient  
(95% ci)
same-day
Reactive 
hyperemia 
index (RHI)
0.46 ± 0.28 0.09 0.28 0.23 (−0.22; 0.60)
Logarithm of 
RHI (lnRHI)
0.23 ± 0.13 0.05 0.37 0.29 (−0.16; 0.64)
Framingham 
RHI (fRHI)
0.30 ± 0.22 0.02 0.51 0.42 (−0.01; 0.72)
Augmentation 
index (AI)
6.86 ± 6.84 0.90 0.81 0.79 (0.56; 0.91)
AI standardized 
to a pulse of 
75/min (AI@75)
7.74 ± 6.97 0.34 0.78 0.76 (0.49; 0.90)
Day-to-day
RHI 0.39 ± 0.30 0.94 0.49 0.51 (0.10; 0.77)
lnRHI 0.20 ± 0.15 0.82 0.51 0.52 (0.13; 0.78)
fRHI 0.23 ± 0.18 0.56 0.66 0.67 (0.33; 0.85)
AI 5.18 ± 3.62 0.84 0.87 0.87 (0.70; 0.94)
AI@75 6.16 ± 3.83 0.22 0.84 0.82 (0.61; 0.93)
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simple and requires minimal training of the operator, thus easily 
accessible for large-scale investigations of risk factors associated 
with endothelial dysfunction and for testing the effect of vasoac-
tive agents.
Two large community-based cohorts have investigated the 
association between RHI score and known cardiovascular 
risk factors (5, 21). They found poor EF to be associated with 
metabolic risk factors including higher BMI, higher cholesterol, 
diabetes, smoking, and female sex (5, 21). Assuming that digital 
EF score correlates with metabolic risk factors, which are key risk 
factors for both large and small vessel disease (34), this method 
could be used to assess the risk of such diseases.
The usability of digital EF measurements for testing vascu-
lar effects of new treatments, assessing stroke prognosis, and 
individualizing stroke prevention is still questionable, however, 
promising. It is mandatory to apply this technique on larger 
cohorts of stroke patients to assess the relation between endothe-
lial dysfunction and risk factors for stroke. In addition, studies 
investigating the association of this EF score with stroke subtypes 
are needed as this has only been investigated by studies with small 
sample sizes (23, 35).
strengths and limitations
Strict standardized conditions were applied during testing to 
minimize confounders (36). All stroke patients were enrolled 
within the first 3 days, and tests were completed within 5 days of 
stroke onset, to lower the effect of difference in vascular instability 
during the acute phase poststroke.
Since a previous study showed good reliability in patients 
with cardiovascular disease (14), we did not correct for known 
cardiovascular disease. Also, none of the included patients had 
a history of recent cardiovascular events prior to the stroke. We 
did, however, exclude patients with paroxysmal atrial fibrillation, 
as studies have shown atrial fibrillation to be associated with 
improved EF upon re-establishment of sinus rhythm (37, 38).
Our study was designed to assess the reliability of repeated 
measurements preformed on the same patient/subject. Thus, 
fallacies caused by differences between the healthy subjects and 
6Hansen et al. Validation of EndoPAT Measurements in Stroke
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